Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 multiple-dose study of brodalumab (KHK4827) in systemic sclerosis
jRCT2080223630Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brodalumab in systemic sclerosis (SSc), sponsored by Kyowa Kirin. Started Aug 2017; status: completed.
02
Drugs
brodalumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on jRCT2080223630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223630.